The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VRTX | +2.61% | +117.32% | +16.78% | +10,234% |
| S&P | +12.9% | +73.65% | +11.66% | +1,705% |
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
A sales partner offered a ray of hope that this company couldn't for itself.
These CRISPR stocks could be big winners for patient investors.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.19B | 10.5% |
| Gross Profit | $2.73B | 10.8% |
| Gross Margin | 85.55% | 0.2% |
| Market Cap | $115.03B | 10.9% |
| Market Cap / Employee | $18.86M | 0.0% |
| Employees | 6.1K | 0.0% |
| Net Income | $1.19B | 30.5% |
| EBITDA | $1.33B | 12.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.95B | -5.7% |
| Accounts Receivable | $2.05B | 27.6% |
| Inventory | 1.7K | 39.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.85B | 11.4% |
| Short Term Debt | $0.00K | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 16.22% | 18.5% |
| Return On Invested Capital | 17.80% | -4.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.14B | -12.5% |
| Operating Free Cash Flow | $1.24B | -9.4% |
| Metric | Q1 2024 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 27.12 | 31.82 | 27.60 | - | |
| Price to Book | 7.59 | 6.93 | 5.84 | 6.65 | 0.11% |
| Price to Sales | 9.55 | 11.39 | 10.12 | 8.60 | -24.80% |
| Price to Tangible Book Value | 8.59 | 7.64 | 6.41 | 7.29 | -3.75% |
| Price to Free Cash Flow TTM | 29.36 | 32.93 | 30.23 | - | |
| Enterprise Value to EBITDA | 88.74 | 114.88 | 89.96 | 72.40 | -26.21% |
| Free Cash Flow Yield | 3.4% | 3.0% | 3.3% | - | |
| Return on Equity | -5.6% | 22.8% | 22.3% | 22.5% | -815.25% |
| Total Debt | $1.65B | $1.53B | $1.83B | $1.85B | 5.54% |
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
We examine three biotech companies' past performances and future outlooks.
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
